BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 35383138)

  • 21. The changing roles of steroid nuclear receptors with prostate cancer progression.
    Savoy RM; Ghosh PM
    Endocr Relat Cancer; 2013 Aug; 20(4):C9-11. PubMed ID: 23744763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and regulation of the estrogen receptors in PC-3 human prostate cancer cells.
    Pisolato R; Lombardi AP; Vicente CM; Lucas TF; Lazari MF; Porto CS
    Steroids; 2016 Mar; 107():74-86. PubMed ID: 26742628
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Distribution and Effects of Estrogen Receptors in Prostate Cancer: Associated Molecular Mechanisms.
    Ramírez-de-Arellano A; Pereira-Suárez AL; Rico-Fuentes C; López-Pulido EI; Villegas-Pineda JC; Sierra-Diaz E
    Front Endocrinol (Lausanne); 2021; 12():811578. PubMed ID: 35087479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients.
    Gross M; Ramirez C; Luthringer D; Nepomuceno E; Vollmer R; Burchette J; Freedland SJ
    Prostate; 2009 Apr; 69(5):520-7. PubMed ID: 19107851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
    Hoffmann J; Sommer A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The emerging roles of orphan nuclear receptors in prostate cancer.
    Wu D; Cheung A; Wang Y; Yu S; Chan FL
    Biochim Biophys Acta; 2016 Aug; 1866(1):23-36. PubMed ID: 27264242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
    Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
    Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estrogen receptors localization and signaling pathways in DU-145 human prostate cancer cells.
    Souza DS; Lombardi APG; Vicente CM; Lucas TFG; Erustes AG; Pereira GJS; Porto CS
    Mol Cell Endocrinol; 2019 Mar; 483():11-23. PubMed ID: 30660702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen and prostate cancer: an eclipsed truth in an androgen-dominated scenario.
    Carruba G
    J Cell Biochem; 2007 Nov; 102(4):899-911. PubMed ID: 17786930
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen receptor-beta activated apoptosis in benign hyperplasia and cancer of the prostate is androgen independent and TNFalpha mediated.
    McPherson SJ; Hussain S; Balanathan P; Hedwards SL; Niranjan B; Grant M; Chandrasiri UP; Toivanen R; Wang Y; Taylor RA; Risbridger GP
    Proc Natl Acad Sci U S A; 2010 Feb; 107(7):3123-8. PubMed ID: 20133657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen receptor overexpression in prostate cancer in type 2 diabetes.
    Lutz SZ; Hennenlotter J; Scharpf MO; Sailer C; Fritsche L; Schmid V; Kantartzis K; Wagner R; Lehmann R; Berti L; Peter A; Staiger H; Fritsche A; Fend F; Todenhöfer T; Stenzl A; Häring HU; Heni M
    Mol Metab; 2018 Feb; 8():158-166. PubMed ID: 29249638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acquisition of androgen independence by human prostate epithelial cells during arsenic-induced malignant transformation.
    Benbrahim-Tallaa L; Webber MM; Waalkes MP
    Environ Health Perspect; 2005 Sep; 113(9):1134-9. PubMed ID: 16140617
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro chronic administration of ERbeta selective ligands and prostate cancer cell growth: hypotheses on the selective role of 3beta-adiol in AR-positive RV1 cells.
    Colciago A; Ruscica M; Mornati O; Piccolella M; Montagnani-Marelli M; Eberini I; Festuccia C; Magni P; Motta M; Negri-Cesi P
    Biomed Res Int; 2014; 2014():801473. PubMed ID: 24877132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen receptor β and 17β-hydroxysteroid dehydrogenase type 6, a growth regulatory pathway that is lost in prostate cancer.
    Muthusamy S; Andersson S; Kim HJ; Butler R; Waage L; Bergerheim U; Gustafsson JÅ
    Proc Natl Acad Sci U S A; 2011 Dec; 108(50):20090-4. PubMed ID: 22114194
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.
    Peacock SO; Fahrenholtz CD; Burnstein KL
    Mol Endocrinol; 2012 Dec; 26(12):1967-79. PubMed ID: 23023561
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.
    Latil A; Bièche I; Vidaud D; Lidereau R; Berthon P; Cussenot O; Vidaud M
    Cancer Res; 2001 Mar; 61(5):1919-26. PubMed ID: 11280747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estrogen receptor β expression and androgen receptor phosphorylation correlate with a poor clinical outcome in hormone-naive prostate cancer and are elevated in castration-resistant disease.
    Zellweger T; Stürm S; Rey S; Zlobec I; Gsponer JR; Rentsch CA; Terracciano LM; Bachmann A; Bubendorf L; Ruiz C
    Endocr Relat Cancer; 2013 Jun; 20(3):403-13. PubMed ID: 23580588
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AKT-independent protection of prostate cancer cells from apoptosis mediated through complex formation between the androgen receptor and FKHR.
    Li P; Lee H; Guo S; Unterman TG; Jenster G; Bai W
    Mol Cell Biol; 2003 Jan; 23(1):104-18. PubMed ID: 12482965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Progesterone Receptor Expression in the Benign Prostatic Hyperplasia and Prostate Cancer Tissues, Relation with Transcription, Growth Factors, Hormone Reception and Components of the AKT/mTOR Signaling Pathway.
    Spirina LV; Kovaleva IV; Usynin EA; Goorbunov AK; Kondakova IV
    Asian Pac J Cancer Prev; 2020 Feb; 21(2):423-429. PubMed ID: 32102520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New therapeutic approach to suppress castration-resistant prostate cancer using ASC-J9 via targeting androgen receptor in selective prostate cells.
    Lai KP; Huang CK; Chang YJ; Chung CY; Yamashita S; Li L; Lee SO; Yeh S; Chang C
    Am J Pathol; 2013 Feb; 182(2):460-73. PubMed ID: 23219429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.